ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Diagnostic performance of LINE-1 repetitive elements in stool DNA for non-invasive detection of colorectal cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe need for accurate, cost-effective, non-invasive screening tests for colorectal cancer (CRC) persists. Repetitive genomic elements like Long Interspersed Nuclear Element-1 (LINE-1), due to their high copy number and cancer-associated alterations, present a promising but unexplored target in stool DNA for CRC detection.
methodsIn this cross-sectional study, stool DNA was extracted from 38 patients with histologically confirmed CRC and 39 healthy controls. The concentration of human DNA was quantified via quantitative PCR targeting two short LINE-1 amplicons (55-bp and 60-bp). Diagnostic performance was evaluated using ROC curve analysis to determine sensitivity, specificity, and predictive values.
resultsThe concentration of stool DNA, measured by LINE-1 qPCR cycle threshold (Ct) values, was significantly higher in CRC patients compared to controls (p < 0.001 for both amplicons). The 60-bp LINE-1 amplicon demonstrated superior diagnostic accuracy with an area under the ROC curve (AUC) of 0.92 (95%CI 0.85-0.98), compared to 0.83 (95%CI 0.73-0.93) for the 55-bp amplicon. At the optimal cut-off (Ct ≤ 24.19), the 60-bp marker achieved a sensitivity of 87.0%, specificity of 78.4%, a positive predictive value (PPV) of 71.4%, and a negative predictive value (NPV) of 90.6%. The 55-bp amplicon showed higher sensitivity (95.7%) but lower specificity (59.5%).
conclusionQuantitative analysis of LINE-1 repetitive elements in stool DNA, particularly using a 60-bp amplicon, demonstrates excellent diagnostic accuracy for detecting CRC. This single-marker, qPCR-based assay represents a simple and potentially low-cost non-invasive strategy, warranting further validation in large-scale screening populations and assessment of its efficacy for detecting precancerous lesions.
Indexed as
Identifiers
42240808What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.